> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Covid Therapy has Reduced Variant Activity: FDA
- URL: https://www.fdaweb.com/lilly-covid-therapy-has-reduced-variant-activity-fda/
- Published: 2022-11-04T12:00:00.000Z
- Updated: 2026-09-14T18:05:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153134

FDA has updated the [Health Care Provider Fact Sheet ](https://www.fda.gov/media/156152/download?ref=fdaweb.com)for Eli Lilly’s Covid-19 antibody therapy bebtelovimab to highlight expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2\. The revised information indicates that bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.

FDA says that at this time, bebtelovimab remains authorized in all U.S. regions until further notice. “Prescribers should monitor [CDC regional variant frequency data](https://covid.cdc.gov/covid-data-tracker/?ref=fdaweb.com#variant-proportions) and refer to the Antiviral Resistance information in the Healthcare Provider Fact Sheet for details regarding specific variants and resistance against SARS-CoV-2 variants in your area, particularly Omicron subvariants BQ.1 and BQ.1.1,” an [agency notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-bebtelovimab?ref=fdaweb.com) says.